Your browser doesn't support javascript.
loading
CALR mutation burden in essential thrombocythemia and disease outcome.
Guglielmelli, Paola; Szuber, Natasha; Gangat, Naseema; Capecchi, Giulio; Maccari, Chiara; Harnois, Michaël; Karrar, Omer; Abdelmagid, Maymona; Balliu, Manjola; Nacca, Elena; Atanasio, Alessandro; Sestini, Ilaria; Désilets, Audrey; Loscocco, Giuseppe Gaetano; Rotunno, Giada; Busque, Lambert; Tefferi, Ayalew; Vannucchi, Alessandro Maria.
Afiliação
  • Guglielmelli P; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Szuber N; University of Montreal, Montreal, QC, Canada.
  • Gangat N; Quebec CML-MPN Research Group, Montreal, QC, Canada.
  • Capecchi G; Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.
  • Maccari C; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Harnois M; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Karrar O; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Abdelmagid M; Quebec CML-MPN Research Group, Montreal, QC, Canada.
  • Balliu M; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Nacca E; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Atanasio A; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Sestini I; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Désilets A; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Loscocco GG; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Rotunno G; University of Montreal, Montreal, QC, Canada.
  • Busque L; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Tefferi A; Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
  • Vannucchi AM; University of Montreal, Montreal, QC, Canada.
Blood ; 143(13): 1310-1314, 2024 Mar 28.
Article em En | MEDLINE | ID: mdl-38252902
ABSTRACT
ABSTRACT Among 281 patients with essential thrombocythemia and calreticulin (CALR) mutation, we found a variant allele frequency of ≥60% to be associated with significantly shortened myelofibrosis-free survival, mostly apparent with CALR type-1 and CALR type-indeterminate mutations.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mielofibrose Primária / Trombocitemia Essencial Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mielofibrose Primária / Trombocitemia Essencial Limite: Humans Idioma: En Revista: Blood Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Itália